SRDX

Surmodics
SRDX

Delisted

SRDX was delisted on the 18th of November, 2025.

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 80%
Negative

Neutral
Business Wire
4 days ago
Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics” or the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that it expects to close its previously announced acquisition (the “Merger”) of the Company by an affiliate of GTCR LLC (“GTCR”) promptly. In a joint status report filed with the United States District Court for the Northern District of Illinois (the “District Court”), the Feder.
Surmodics Announces FTC Does Not Intend to Appeal Denial of Injunction, Order Preventing Closing Set to Expire Today
Positive
Benzinga
10 days ago
Federal Judge Clears Path For GTCR's Takeover Of Surmodics After FTC Challenge
The United States District Court for the Northern District of Illinois on Tuesday denied a request by the U.S. Federal Trade Commission and certain state regulators to issue a preliminary injunction that would have prevented the proposed acquisition of Surmodics Inc. (NASDAQ:SRDX) by GTCR.
Federal Judge Clears Path For GTCR's Takeover Of Surmodics After FTC Challenge
Neutral
Business Wire
11 days ago
Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics” or the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States District Court for the Northern District of Illinois (the “District Court”) has denied a request by the U.S. Federal Trade Commission (the “FTC”) and certain state regulators to issue a preliminary injunction that would have prevented the Company and GTCR.
Surmodics Announces U.S. District Court Denies Request for Preliminary Injunction to Block Proposed Acquisition by GTCR
Neutral
Business Wire
17 days ago
Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that results from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia from its PROWL registry study were presented on November 3rd at an industry-sponsored session at the 23rd Annual VIVA Conference in Las Vegas, NV. PROWL national co-principal investigators Dr. Sean Lyden and.
Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations
Neutral
Business Wire
18 days ago
Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that Dr. Sean Lyden, Dr. Joseph Campbell, and Dr. Peter Monteleone, will present and discuss updated safety and performance data from the PROWL registry on 160 patients with symptomatic lower extremity (infrainguinal) vessels treated with the Pounce™ Thrombectomy Platform. The presentation will be held on Mon.
Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3
Positive
Zacks Investment Research
3 months ago
SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts
Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.
SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts
Positive
Zacks Investment Research
3 months ago
SurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
SurModics (SRDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Positive
Zacks Investment Research
3 months ago
SurModics (SRDX) Q3 Earnings and Revenues Beat Estimates
SurModics (SRDX) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.21 per share. This compares to a loss of $0.27 per share a year ago.
SurModics (SRDX) Q3 Earnings and Revenues Beat Estimates
Positive
The Motley Fool
3 months ago
Surmodics (SRDX) Q3 EPS Turns Positive
Surmodics (SRDX) Q3 EPS Turns Positive
Surmodics (SRDX) Q3 EPS Turns Positive
Neutral
Business Wire
3 months ago
Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its third quarter ended June 30, 2025, and updated its financial guidance for the fiscal year ending September 30, 2025. Third Quarter Fiscal 2025 Financial Summary Total Revenue of $29.6 million, a decrease of 3% year-over-year Total Revenue excluding SurVeil™ drug-coated balloon (“DCB”).
Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance